Clinical Trials Browser

INDUSTRY × AZD 6244 × Dermatologic × Clear all

NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

Phase 1 Completed

BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT02586987 2019-11-18

A Study to Assess the Safety, Tolerability and Anti-tumour Activity of Ascending Doses of Selumetinib in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours

Phase 1 Completed

BreastDermatologicGastrointestinalThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Lung Neoplasms, Melanoma, Colorectal Neoplasms, Disease Progression

NCT01974752 2017-01-05

SUMIT

Phase 3 Completed

152 enrolled 14 charts

Uveal Melanoma, Neoplasm Metastasis

NCT00936221 2016-03-14

Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients

Phase 2 Completed

385 enrolled 11 charts

Melanoma

NCT00338130 2014-08-13

Randomised Study to Compare the Efficacy of AZD6244 vs TMZ

Phase 2 Completed

Melanoma

NCT00710515 2014-08-13

Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies

Phase 1 Completed

Melanoma